Neuroprotective functions of erythropoietin (Epo) are thought to involve a heteroreceptor composed of both Epo receptor (Epo-R) and common β chain (βc). Here, we measured the response of hippocampal Epo system components (Epo, Epo-R and βc) during neurodegenerative processes following pilocarpine-induced status epilepticus (SE), and examined whether recombinant human Epo (rHuEpo) could support neuronal survival. We evidence that Epo is induced in astroglia following SE, in particular within areas displaying delayed neuronal death. In addition, we demonstrate for the first time that rHuEpo reduces considerably hippocampal neurodegeneration following SE. rHuEpo may thus supplement astroglial induction of Epo to promote enhanced hippocampal neuronal survival following SE. We also show that Epo-R is expressed by neurons and astrocytes mainly, while βc is barely detectable in basal conditions and induced in reactive microglia exclusively following SE. Altogether, our results suggest that Epo/rHuEpo exerts neuroprotection, through Epo-R signaling and independently of βc, and, therefore, may be antiepileptogenic.
Introduction
Erythropoietin (Epo) was originally described for its role in hematopoiesis, which consists of increasing red blood cells (Jelkmann, 1992) by protecting erythroid progenitors against apoptosis (Ghezzi and Brines, 2004) . Epo and its receptor (Epo-R) are expressed in rodent and human brain, in cultured neurons, astrocytes, oligodendrocytes, microglia, and endothelial cells (Marti et al., 1996; Juul et al., 1999; Chin et al., 2000; Siren et al., 2001; Hasselblatt et al., 2006) , which has led to studies of additional biological roles of Epo. Exogenous administration of Epo revealed neuroprotective activity in vitro and in vivo in models of central and peripheral neuronal injury occurring in the contexts of trauma, stroke and inflammation (Juul et al., 2004; Campana and Myers, 2003; Maiese et al., 2004; Brines and Cerami, 2005) .
Recombinant human Epo (rHuEpo)-administered peripherally crosses the blood-brain barrier (BBB) (Brines et al., 2000; Ehrenreich et al., 2004; Juul et al., 2004; Gorio et al., 2005) . Studies in rodent models of temporal lobe epilepsy (TLE) revealed significant effects of rHuEpo in antagonizing the development of status epilepticus (SE), but did not determine whether rHuEpo was neuroprotective (Brines et al., 2000; Uzum et al., 2006) . Interestingly, many of the programmed cell death pathways involved in animal models of TLE (Henshall and Simon, 2005) are those targeted by Epo (Maiese et al., 2004; Brines and Cerami, 2005) .
Possible adverse effects of rHuEpo, such as increase in blood pressure, thrombosis, tumor expansion, and mortality (Maiese et al., 2004; Brines and Cerami, 2005) have spurred the development of Epo derivatives that are neuroprotective, but not erythropoietic (Leist et al., 2004 
